Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06503367 · ClinicalTrials.gov registry record
Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy
A clinical trial of LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\), sponsored by Nationwide Children's Hospital.
- Recruiting
- Registry status
- 44
- Enrollment target
- 14
- Study locations
NCT06503367: Recruiting study of LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\), sponsored by Nationwide Children's Hospital.
NCT06503367 is a study of LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\) that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 44 participants. The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06503367, a study of LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\), is actively recruiting participants, sponsored by Nationwide Children's Hospital.
- RECRUITING
- Registry status
- 44 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this observational study is to understand how young children with LAMA2-related dystrophy move and change over time. We will also learn about how this condition impacts other body systems. Participants will undergo: * Neuromuscular assessments * Blood collections * Swallowing and breathing assessments * Questionnaires
Primary Outcome
The Neuromuscular GRO is a 50-item assessment that measures a child's gross motor function when lying down, sitting, crawling, walking, jumping, and climbing stairs.
Conditions Studied
Study Locations (14)
California
- University of California, Los Angeles - Los Angeles
- Stanford University - Stanford
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Iowa
- University of Iowa Stead Family Children's Hospital - Iowa City
Maryland
- National Institute of Neurological Disorders and Stroke, NIH - Bethesda
Massachusetts
- Boston Children's Hospital - Boston
Minnesota
- University of Minnesota - Saint Paul
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2028-09 |
What NCT06503367 shows while recruiting
NCT06503367 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.
The record links to 1 condition, with LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\) appearing as the primary indexed condition, and to 0 interventions.
NCT06503367 lists 14 locations in 12 states (California, Ohio, Illinois).
Frequently Asked Questions
What is clinical trial NCT06503367 about?
NCT06503367 is a clinical study titled "Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy". The goal of this observational study is to understand how young children with LAMA2-related dystrophy move and change over time. We will also learn about how this condition impacts other body systems. Participants will undergo: * Neuromuscular assessments * Blood collections * Swallowing and breat...
What is the current status of trial NCT06503367?
This trial is currently recruiting. The enrollment target is 44 participants. The study started on 2025-05-12. Estimated completion is 2028-09.
What conditions does trial NCT06503367 study?
This clinical trial studies the following conditions: LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\).
Who is sponsoring clinical trial NCT06503367?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06503367 being conducted?
This trial has 14 study locations across California, Illinois, Iowa, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI